Read our Recent Headlines


September 18 Biotech Update

Not much happening in the sector or markets outside of the ongoing issues in the Middle East. We will likely get a press conference today that blames Iran for the.

September 17 Biotech Update

So I was thinking that any response to the attacks on Saudi Arabia would happen sooner rather than later but I am no longer convinced that remains the case.  Clearly.

September 16 Biotech Update

It is looking like a macro week, although this could resolve itself fairly quickly.  The attacks on the ARAMCO production facility is likely to have long term effects on oil.

Initiating: Turning Point Therapeutics

San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock.

September 11th Biotech Update

(Sorry for the delay.  The site worked but we had an issue with posting new articles.  It is now fixed) The resilience of the sector is a little surprising and.

September 10 Biotech Update

Surprise.  The sector is weak.  I am a little surprised that we are not see a faster sell off as clearly there is no momentum and we have broken support. .

September 9th Biotech Update

We have some interesting news to start the week and of course it leads to a flat sector with the broader market green.  It seems like the sector is underperforming.

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!